Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 3 versus TERCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 3 versus TERCONAZOLE.
MONISTAT 3 vs TERCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Terconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function.
One vaginal suppository (200 mg miconazole nitrate) intravaginally at bedtime for 3 consecutive days; or one applicatorful (5 g) of 4% vaginal cream intravaginally at bedtime for 7 days.
Intravaginal cream (0.4%, 0.8%): one applicatorful (approximately 5 g) intravaginally once daily at bedtime for 7 days; vaginal suppository (80 mg): one suppository intravaginally once daily at bedtime for 3 days.
None Documented
None Documented
Clinical Note
moderateTerconazole + Tranilast
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast."
Clinical Note
moderateTerconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic acid."
Clinical Note
moderateTerconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide."
Clinical Note
moderateTerconazole + Risedronic acid
Terminal elimination half-life is approximately 30 hours after topical vaginal application; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 25-37 hours, allowing once-daily dosing for vaginal infections.
Primarily fecal (97%) via biliary excretion; renal excretion of unchanged drug is negligible (<1%).
Primarily hepatic metabolism with biliary excretion; approximately 60-80% of the dose is excreted in feces as metabolites, and about 20% in urine mostly as inactive metabolites.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Terconazole is combined with Risedronic acid."